Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
56 participants
INTERVENTIONAL
2006-11-30
2008-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Superior Silybin Bioavailability in Healthy Volunteers
NCT03440164
An Intervention Study of Compound Silymarin in Patients With Non-alcoholic Fatty Liver Disease
NCT05497765
Efficacy of Silymarin for Acute Hepatitis
NCT00412763
Cholic Acid for Hepatic Steatosis in Lipodystrophy
NCT00457639
Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis
NCT02024295
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Placebo and 140 mg single dose + every 8 hours
Placebo
Placebo
Silymarin
140 mg every 8 hours
Group 2
Placebo and 280 mg single dose
Placebo
Placebo
Silymarin
280 mg single dose
Group 3
Placebo and 280mg every 8 hours
Placebo
Placebo
Silymarin
280 mg every 8 hours
Group 4
Placebo and 280 single dose + every 8 hours
Placebo
Placebo
Silymarin
280 mg single dose + every 8 hours
Group 5
Placebo and 560 mg single dose + every 8 hours
Placebo
Placebo
Silymarin
560 mg single dose + every 8 hours
Group 6
Placebo and 560 mg single dose + every 8 hours
Placebo
Placebo
Silymarin
560 mg single dose + every 8 hours
Group 7
Placebo and 700 mg single dose + every 8 hours
Placebo
Placebo
Silymarin
700 mg single dose + every 8 hours
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Placebo
Silymarin
140 mg every 8 hours
Silymarin
280 mg single dose
Silymarin
280 mg single dose + every 8 hours
Silymarin
560 mg single dose + every 8 hours
Silymarin
560 mg single dose + every 8 hours
Silymarin
280 mg every 8 hours
Silymarin
700 mg single dose + every 8 hours
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males or females; age at least 18 years at screening
* Abnormal ALT \> 65 IU/L (ie, approximately 1.5 x upper limit of normal)
* Negative urine pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of silymarin. Females of childbearing potential must be using two reliable forms of effective contraception during the study (while on drug and during follow-up)
* Hepatitis C virus (HCV) patients
* Previous treatment with any interferon-based therapy without sustained virological response.
* Serum HCV RNA above quantifiable level of detection by the assay, within 1 year of screening and after the end of therapy
* No antiviral therapy for at least 6 months prior to screening visit
* Nonalcoholic fatty liver disease (NAFLD) patients:
* Liver biopsy compatible with NAFLD within 3 years of screening
* Absence of other liver diseases by serological screening (anti-HCV, HBsAg), historical serological data from within 3 years of screening is acceptable.
* Before entering the study, subjects must agree not to consume alcohol for 48 hours prior to PK sampling days or while on study.
Exclusion Criteria
* Use of silymarin or other milk thistle preparations within 30 days of screening
* Use of other antioxidants such as vitamin E, vitamin C, glutathione, alpha-tocopherol, within 30 days of screening. A multivitamin at standard doses will be allowed.
* Allergy/sensitivity to milk thistle or its preparations
* Use of silymarin or other antioxidants (as above) during the screening period.
* Use of warfarin, metronidazole or chronic use of acetaminophen greater than two gram per day
* Previous liver biopsy that demonstrated presence of cirrhosis
* Previous liver biopsy that demonstrated greater than or equal to 15% steatosis or evidence of steatohepatitis for HCV cohort
* Positive test for anti-HIV or HBsAg within 3 years of screening
* Positive urine drug screen for drugs of abuse at screening
* Alcohol consumption of more than one drink or equivalent (\>12 grams) per day. Patients who consumed more than this in the past must have maintained a level 12 grams or less per day of alcohol consumption for at least six months prior to screening.
* History of other chronic liver disease, including metabolic diseases, documented by appropriate test(s)
* Women with ongoing pregnancy or breast-feeding, or contemplating pregnancy
* Platelet count \<130,000 cells/mm3.
* Serum creatinine level \>1.5 times the upper limit of normal at screening, or CrCl 60 cc/min, or currently on dialysis. The creatinine clearance (CrCl) will be calculated according to Cockcroft-Gault.
* Evidence of alcohol or drug abuse within 6 months prior to screening
* Evidence of decompensated liver disease defined as any of the following: serum albumin \<3.2 g/dl, total bilirubin \> 1.5 mg/dl, or PT/INR \> 1.3 times normal at screening, or history or presence of ascites or encephalopathy, or bleeding from esophageal varices
* History or other evidence of severe illness or any other conditions that would make the patient, in the opinion of the investigator, unsuitable for the study (such as poorly controlled psychiatric disease, coronary artery disease, or active gastrointestinal conditions that might interfere with drug absorption)
* History of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hepatitis, autoimmune hemolytic anemia, severe psoriasis, rheumatoid arthritis) that could affect inflammatory biomarkers
* History of solid organ or bone marrow transplantation
* History of thyroid disease poorly controlled on prescribed medications
* Use of oral steroids within 30 days prior to screening
* Concurrent medications that are CYP3A4 inducers
* Inability or unwillingness to provide informed consent or abide by the study protocol
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
National Center for Complementary and Integrative Health (NCCIH)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
NCCAM/NIDDK/UNC/UPenn/TJU/BIDMC/UPitt
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
K. Rajender Reddy, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pennsylvania
Victor Navarro, MD
Role: PRINCIPAL_INVESTIGATOR
Thomas Jefferson University
Nezam Afdhal, MD
Role: PRINCIPAL_INVESTIGATOR
Beth Israel Deaconess Medical Center
Michael Fried, MD
Role: PRINCIPAL_INVESTIGATOR
University of North Carolina
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
University of Pittsburgh, Graduate School of Public Health
Pittsburgh, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Schrieber SJ, Hawke RL, Wen Z, Smith PC, Reddy KR, Wahed AS, Belle SH, Afdhal NH, Navarro VJ, Meyers CM, Doo E, Fried MW. Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C. Drug Metab Dispos. 2011 Dec;39(12):2182-90. doi: 10.1124/dmd.111.040212. Epub 2011 Aug 24.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIH grant # U01-AT0035661
Identifier Type: -
Identifier Source: secondary_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.